Open-Label Treatment With MPC-7869 for Patients With Alzheimer's Who Previously Participated in an MPC-7869 Protocol

PHASE3TerminatedINTERVENTIONAL
Enrollment

1,000

Participants

Timeline

Start Date

September 30, 2006

Study Completion Date

December 31, 2008

Conditions
Alzheimer's Disease
Interventions
DRUG

MPC-7869

800 mg BID Oral dosing

Trial Locations (90)

Unknown

Alabaster

Huntsville

Phoenix

Sun City

Tucson

Costa Mesa

Irvine

Lafayette

Laguna Hills

Long Beach

Rancho Mirage

Sacramento

San Diego

San Francisco

Vista

Danbury

Darien

New Haven

Washington D.C.

Deerfield Beach

Fort Meyers

Fort Myers

Hollywood

Jacksonville

Miami

Naples

Sunrise

Tampa

West Palm Beach

Atlanta

Chicago

Fort Wayne

Indianapolis

Lexington

Baltimore

Glen Burnie

Boston

West Yarmouth

Ann Arbor

Grand Rapids

Rochester

St Louis

Lebanon

Kenilworth

Morristown

Princeton

Stratford

Albuquerque

Albany

Brooklyn

Elmsford

New York

Olean

Rochester

Syracuse

Durham

Raleigh

Centerville

Columbus

Toledo

Oklahoma City

Eugene

Portland

Jenkintown

Philadelphia

Pittsburgh

Scotland

East Providence

Beaufort

Charleston

Greer

Memphis

Nashville

Dallas

Houston

San Antonio

Ogden

Salt Lake City

Bennington

Alexandria

Charlottesville

Virginia Beach

Middleton

Milwaukee

Winnepeg

Halifax

Kingston

Ottawa

Toronto

Regina

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Myrexis Inc.

INDUSTRY

NCT00380276 - Open-Label Treatment With MPC-7869 for Patients With Alzheimer's Who Previously Participated in an MPC-7869 Protocol | Biotech Hunter | Biotech Hunter